Related content

Dopamine receptor agonists in the therapy of Parkinson’s disease

By Foley P.   Gerlach M.   Double K. L.   Riederer P.  

Journal of Neural Transmission, Vol. 111, Iss. 10-11, 2004-10 ,pp. : 1375-1446

Springer Publishing Company

Access to resources Recommend Favorite

Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery

By Yamamoto Mitsutoshi   Uesugi Tadahisa  

Journal of Neurology, Vol. 254, Iss. 5, 2007-09 ,pp. : 74-78

Springer Publishing Company

Access to resources Recommend Favorite

Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists

By Roth T.   Rye D.B.   Borchert L.D.   Bartlett C.   Bliwise D.L.   Cantor C.   Gorell J.M.   Hubble J.P.   Musch B.   Olanow C.W.   Pollak C.   Stern M.B.   Watts R.L.  

Sleep Medicine, Vol. 4, Iss. 4, 2003-07 ,pp. : 275-280

Elsevier

Access to resources Recommend Favorite

A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson’s disease – a subjective view

By Horowski R.  

Journal of Neural Transmission, Vol. 114, Iss. 1, 2007-01 ,pp. : 127-134

Springer Publishing Company

Access to resources Recommend Favorite

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

By de la Fuente-Fernández Raúl   Sossi Vesna   Huang Zhigao   Furtado Sarah   Lu Jian-Qiang   Calne Donald B.   Ruth Thomas J.   Stoessl A. Jon  

Brain, Vol. 127, Iss. 12, 2004-12 ,pp. : 2747-2754

Oxford University Press

Access to resources Recommend Favorite